Cite
HARVARD Citation
Chan, A. et al. (2022). A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma. American journal of clinical oncology. p. . [Online].